Pick · 8.0% · large · Health Care · last 125.63
Entry 115.00–122.00 · Stop 109.00 · Target 148.00 · Buy ≈ 32 shares (≈ $4,020 at 125.63)
Thesis (long, position, conviction 58)
Bull: Halozyme's royalty/ENHANZE licensing model is firing on all cylinders: Q2 2026 revenue grew 48% YoY to $481M with GAAP net income of $229.9M and diluted EPS of $1.90 (F-HALO-4, F-HALO-5, F-HALO-6). Management raised full-year 2026 guidance to $1.835-1.910B revenue, $1.220-1.245B royalty revenue, $1.225-1.280B adjusted EBITDA and $8.65-9.00 non-GAAP EPS (F-HALO-7) — at the current price that implies roughly 14x forward non-GAAP earnings for a high-margin, asset-light royalty business, which is not demanding for this growth rate. The company has already signed five new ENHANZE/Hypercon deals through July, beating its full-year target of three (F-HALO-8), expanding the long-dated royalty pipeline. Sell-side sentiment is uniformly positive (3 strong buy, 10 buy, 3 hold, zero sells as of Oct 1) (F-HALO-11), and the stock's uptrend is confirmed by price above all key moving averages with strong 3-month relative strength versus SPY (+51.1pp) (F-HALO-2, F-HALO-3). Q3 earnings on Nov 5 is a near-term catalyst that could extend the guidance-raise narrative given consensus estimates (~$500.7M revenue, $2.40 EPS) imply continued acceleration.
Bear: The stock is technically extreme: RSI14 of 73.98, at a fresh 52-week/all-time closing high, up 54% in three months (F-HALO-1, F-HALO-2, F-HALO-3) — a classic setup for a sharp mean-reversion pullback, especially heading into a binary earnings event on Nov 5 where any guidance miss or "sell the news" reaction could be amplified by crowded positioning. The $1.5B convertible note issuance at a 1.50% coupon adds leverage and creates an overhang/dilution risk above the $139.84 conversion price (F-HALO-9, F-HALO-10), capping upside somewhat and signaling management saw the current price as an attractive level to raise capital. The brief's financial data stops at Q2 2026, so we lack visibility into actual Q3 results or any post-earnings commentary; everything bullish here is based on data already two-plus months old relative to today.
Valuation: On the brief's raised 2026 guidance ($8.65-9.00 non-GAAP EPS), HALO trades near 14x forward non-GAAP earnings for a royalty-based business guiding to high-40s% revenue growth and expanding EBITDA margins — a reasonable, not stretched, fundamental multiple. However, price action has run well ahead of the fundamental re-rating (54% in 3 months vs. 48% revenue growth), so the stock is pricing in continued beat-and-raise execution; the risk is technical/sentiment extension rather than fundamental overvaluation. No explicit FCF yield or peer multiple comparison is available in the brief, so this view relies solely on the guided EPS range.
Catalysts
2026-11-05: Q3 2026 earnings report, consensus estimates ~$500.7M revenue and ~$2.40 EPS, following the Q2 guidance raise
2026-11-05: Progress toward/beyond the 5+ ENHANZE/Hypercon collaboration deals signed in 2026 could be updated at Q3 report
Facts
F-HALO-1: HALO closed at $125.63 on 2026-10-23, its highest closing price in the supplied 52-week series. (as of 2026-10-23)[E6447]
F-HALO-2: The stock’s 3-month return through 2026-10-23 was 54.19%, and its 3-month relative strength versus SPY was 51.1 percentage points. (as of 2026-10-23)[E6447]
F-HALO-3: At the 2026-10-23 close, HALO was above its 20-day, 50-day and 200-day moving averages of $115.17, $111.14 and $81.94, respectively; its RSI14 was 73.98. (as of 2026-10-23)[E6447]
F-HALO-4: Revenue for the quarter ended 2026-06-30 was $481.0 million, compared with $325.7 million for the quarter ended 2025-06-30; Halozyme’s release reported year-over-year growth of 48%. (as of 2026-08-06)[E6448, E7184]source
F-HALO-5: For the quarter ended 2026-06-30, Halozyme reported GAAP operating income of $287.7 million and net income of $229.9 million. (as of 2026-06-30)[E6448]
F-HALO-6: Diluted GAAP EPS was $1.90 for the quarter ended 2026-06-30, versus $1.33 for the quarter ended 2025-06-30. (as of 2026-06-30)[E6448]
F-HALO-7: On 2026-08-06, Halozyme raised its 2026 full-year guidance to revenue of $1.835–$1.910 billion, royalty revenue of $1.220–$1.245 billion, adjusted EBITDA of $1.225–$1.280 billion and non-GAAP diluted EPS of $8.65–$9.00. (as of 2026-08-06)[E7184]source
F-HALO-8: Halozyme reported signing five new ENHANZE and Hypercon collaboration agreements through July 2026, exceeding its stated goal of three for the full year. (as of 2026-08-06)[E7184]source
F-HALO-9: On 2026-09-22, Halozyme completed a $1.5 billion offering of 1.50% convertible senior notes due 2033 and reported net proceeds of approximately $1.471 billion. (as of 2026-09-22)[E7165]source
F-HALO-10: The 2033 notes have an initial conversion price of approximately $139.84 per share; the notes are unsecured and convertible into cash and, if applicable, common shares at the company’s election. (as of 2026-09-22)[E7185]source
F-HALO-11: The latest supplied analyst recommendation count, for 2026-10-01, was 3 strong buy, 10 buy and 3 hold, with no sell or strong-sell recommendations. (as of 2026-10-01)[E7173]
What would change the view
A daily close below $109 (just under the 50-day MA) invalidating the uptrend thesis
Q3 2026 results (due ~2026-11-05) showing revenue growth decelerating meaningfully below the ~48% YoY pace or guidance being cut
RSI14 falling below 50 on declining price, confirming momentum has broken
Evidence of accelerating share issuance/dilution tied to the 2033 convertible notes ahead of the 2033 maturity
Data quality
Quality score 100/100.
Gap: The quote block is timestamped 2026-10-24, after the supplied as-of date of 2026-10-23, and reports a 52-week high of $125.43, below the 2026-10-23 daily-bar close of $125.63. Price and trend facts use the dated daily-bar series.
Gap: The supplied quarterly financial series ends on 2026-06-30 and does not include reported third-quarter 2026 results.
Red flag: The $1.5 billion 2033 convertible-note issuance adds debt and could result in share issuance upon conversion; the initial conversion price is approximately $139.84 per share. (E7165, E7185)